Lars Ingemann

Lars became an Operating Partner at ArchiMed in October 2021 after joining as a Strategic Partner in 2020.
At ArchiMed Lars is particularly focused on the Biopharma sector with expertise in pharma, in-vivo and in-vitro diagnostics, nutraceuticals, respiratory medicine, dermatology and allergy.
Lars has a solid operational background from the Biopharma industry.
He spent most of his career in the allergy segment and has been respectively EVP and CCO for two global leading companies in the allergy industry.
As EVP of International Operations, Lars headed ALK’s commercial expansion to become an internationally established player and eventually the world leader in the allergy segment.
Lars has especially been engaged in setting up subsidiaries as well as leading several post-acquisition integrations and cross cultural and geographical mergers acting as chairman of subsidiaries.
His experience covers all markets from Europe and USA to China and Japan.
Lars has also been CCO of Allergopharma, the allergy dedicated subsidiary of Merck KGaA.
Recently, Lars has engaged as board member, interim director and strategic advisor for start-ups and SME pharma companies and biotech ventures.
Furthermore he has been leading several business development projects in the Life Science sector.
Lars Ingemann holds a Masters degree of Pharmaceutical Science from Copenhagen University.
He is a citizen of Denmark and speaks fluent English.